Ò¼ºÅÓéÀÖ

×ðÖØ¿ÆÑ§ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü

ѧÊõ¶¯Ì¬

ѧÊõ¶¯Ì¬




Ò¼ºÅÓéÀÖ¹¹½¨LOXO-292ÄÍҩ˫ͻ±ä¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÖÆ¼Á¿ª·¢


Ðû²¼Ê±¼ä£º

2021-06-22

RET£¨Rearranged during transfection£©»ùÒòÓÚ1985ÄêÊ×´ÎÔÚÈËTÁܰÍÁöϸ°ûÖз¢Ã÷£¬£¬£¬ÇÒ±»ÅжÏΪһ¸öÔ­°©»ùÒò£¬£¬£¬RET»ùÒòλÓÚÈËÀà10ºÅ³£È¾É«Ì峤±Û£¨10q11.2£©£¬£¬£¬±àÂëÒ»ÖÖ±£´æÓÚϸ°ûĤÉϵÄÊÜÌåÀÒ°±Ëἤø£¨RTK£©[1]¡£¡£¡£ ¡£RETÂѰ×ÔÚ³ÉÊìÀú³ÌÖУ¬£¬£¬ÂѰ×ǰÌåͨ¹ý²î±ðµÄÑ¡ÔñÐÔ¼ôÇз½·¨£¬£¬£¬Ö÷ÒªÐγÉÁ½ÖÖÂѰ×ÑÇÐÍRET-9ºÍRET-51¡£¡£¡£ ¡£RET¼¤Ã¸±»Éñ¾­½ºÖÊϸ°ûϵȪԴµÄÉñı»®ÑøÉú³¤Òò×ÓGDNF¼¤»î£¬£¬£¬GFNFÓëGFRα1Á¬ÏµÐγÉGDNF-GFRα1¸´ºÏÎ£¬£¬´Ë¸´ºÏÎïÔÙÓëRETÁ¬ÏµÐγÉÈý¸´ºÏÌ壬£¬£¬ÒýÆðRETµÄ¶þ¾Û»¯£¬£¬£¬²¢ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬£¬£¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·[2]£¬£¬£¬°üÀ¨RAS/MARK¡¢PI3K/AKT¡¢PLCγ/PKCµÈÐźÅͨ·£¬£¬£¬½ø¶øÒýÆðϸ°ûµÄÔöÖ³·Ö½â¡¢Ç¨áã¡¢ÔÙÉúºÍÉú³¤µÈ[1]¡£¡£¡£ ¡£

 

ͼ1. a) RET¼¤Ã¸½á¹¹;b) RET¼¤Ã¸»î»¯»úÖÆ¼°ÐźÅͨ·¡£¡£¡£ ¡£

(ͼƬȪԴÓڲο¼×ÊÁÏ[2])

 

RET»ùÒòÖ°©»úÖÆ£¬£¬£¬Ö÷ÒªÓлùÒòÈںϡ¢µãÍ»±ä¡¢»ùÒòÀ©ÔöºÍȾɫÌåÖØÅŵÈ[3]¡£¡£¡£ ¡£È¾É«ÌåµÄÖØ×é³£»£»£»áµ¼ÖÂRET»ùÒòÖÐÖÐÖ¹ÁѺóÓë²î±ðµÄÉÏÓλùÒò±¬·¢Èںϣ¬£¬£¬½ø¶øÐγÉÇý¶¯Ö×Áöϸ°ûÔöÖ³µÄÈںϻùÒò¡£¡£¡£ ¡£ÔÚ1990ÄêºÍ2012ÄêÏȺóÔÚ¼××´ÏÙÈéÍ·×´°©¡¢·ÎÏÙ°©ºÍÂýÐÔËèϵ°×Ѫ²¡Öз¢Ã÷ÕâÒ»±äÒì¡£¡£¡£ ¡£ÆäÖÐÈںϻùÒòÖ÷ÒªÓУºKIF5B-RET£¨×î¶à£©£¬£¬£¬CCDC6-RETºÍNCOA4-RET£»£»£»RET»ùÒòÔÚNSCLC»¼ÕßÖ÷ÒªÒÔRET»ùÒòÈÚºÏÐÎʽ±¬·¢¸Ä±ä£¬£¬£¬Ñо¿ÏÔʾ·ÇСϸ°û·Î°©ÖÐKIF5B©\RETÈÚºÏÔ¼Õ¼ËùÓÐRETÈÚºÏµÄ 68.3 %£¬£¬£¬Æä´ÎΪCCDC6©\RET (16.8 %)¼°NCOA4©\RET (1.2 %)[4]¡£¡£¡£ ¡£ËäÈ»RET»ùÒòÔÚNSCLC»¼ÕßÖеķ¢²¡ÂʽöΪ1.4 %-2.5 %£¬£¬£¬¿ÉÊÇÎÒ¹úµÄ»¼Õß»ùÊýºÜÊǴ󣬣¬£¬Òò¶øÐ¯´øRET»ùÒòÈںϵÄNSCLC»¼Õß²¢²»ÉÙ¼û[5]¡£¡£¡£ ¡£µãÍ»±ä¶àλÓÚGate keeper²Ð»ù£¬£¬£¬Ö÷ÒªÊÇV804λµã£¨V804M£¬£¬£¬V804L£©£¬£¬£¬»¹°üÀ¨ÈܼÁÇ°ÑØÍ»±äG810λµã£¨G810R£¬£¬£¬G810S£¬£¬£¬G810C£¬£¬£¬G810A£¬£¬£¬G810V£©¡¢M918TºÍC634λµã£¨C634R£¬£¬£¬C634G£¬£¬£¬C634F£¬£¬£¬C634S£¬£¬£¬C634W£¬£¬£¬C634Y£¬£¬£¬C634K£©Í»±äµÈ[1]¡£¡£¡£ ¡£

 

A

ͼ2. ²î±ð°©Ö¢ÖÐRET»ùÒò¸Ä±äµÄ¸ÅÊö¡£¡£¡£ ¡£

(ͼƬȪԴÓڲο¼×ÊÁÏ[3])

 

A

ͼ3. RET»ùÒòµÄÖ÷ÒªÈںϷ½·¨ºÍµãÍ»±äλµã¡£¡£¡£ ¡£

(ͼƬȪԴÓڲο¼×ÊÁÏ[1])

 

2011ÄêºÍ2013Ä꣬£¬£¬FDAºÍEMA»®·ÖÅú×¼VandetanibºÍCabozantinibÓÃÓÚÖÎÁÆÏ£ÍûµÄÍíÆÚµÄMTC»¼Õߣ¬£¬£¬²¢ÒÑÔÚRETÈÚºÏÑôÐÔNSCLC»¼ÕßÖÐÏÔʾ³ö»îÐÔ[1]¡£¡£¡£ ¡£µ«ÉÏÊöÒ©ÎïÕûÌ幨ÓÚRET»ùÒòÈÚºÏÍ»±äµÄ°ÐÏòÌØÒìÐÔ²¢²»Ç¿£¬£¬£¬Æä²»µ«ÒÖÖÆRETÂѰ×Ðźţ¬£¬£¬Í¬Ê±»áÒÖÖÆVEGFR¡¢EGFRµÈÆäËûÂѰף¬£¬£¬ÓÐÓÃÐÔÏà¶Ô½Ï²î£¬£¬£¬ÇÒ¸±×÷ÓúͷǰÐÏò¶¾ÐÔÔöÌí¡£¡£¡£ ¡£2020Äê5ÔÂ9ÈÕ£¬£¬£¬FDA¼ÓËÙÅú×¼ÁËLoxo Oncology¹«Ë¾(ÀñÀ´ÆìÏÂ)selpercatinib(LOXO-292£¬£¬£¬Retevmo)ÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁƲ¿·ÖRETÈںϻùÒòµÄ·ÇСϸ°û·Î°©³ÉÈË»¼Õߣ¬£¬£¬ºÍÍíÆÚRETÍ»±äÑôÐÔ¼××´ÏÙËèÑù°©(MTC)»¼Õß¼°ÍíÆÚ»ò×ªÒÆµÄRETÈÚºÏÑôÐÔ¼××´ÏÙ°©»¼Õß¡£¡£¡£ ¡£ÕâÊÇFDAÅú×¼µÄÊ׿î¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÖÆ¼Á¡£¡£¡£ ¡£Selpercatinib(LOXO-292)ÊǿڷþÓÃÒ©µÄATP¾ºÕùÐÔС·Ö×ÓRET¼¤Ã¸ÒÖÖÆ¼Á£¬£¬£¬Ëü¾ßÓд©Í¸ÖÐÊàÉñ¾­ÏµÍ³(CNS)µÄÄÜÁ¦£¬£¬£¬²¢ÇÒ¿ÉÒÔ°ÐÏò¼¤»îÐÔRETÈںϡ¢µãÍ»±äºÍijЩ»ñµÃÐÔÄÍÒ©Í»±ä(¶Ô°üÀ¨KIF5B-RETºÍCCDC6-RETÈÚºÏÀàÐÍ£¬£¬£¬ÒÔ¼°RET-V804L/MºÍM918TÄÍÒ©Í»±äÃô¸Ð)[1]¡£¡£¡£ ¡£2020Äê9ÔÂ5ÈÕ£¬£¬£¬FDAÅú×¼À¶Í¼¹«Ë¾(Blueprint Medicines Corporation)¿ª·¢µÄRETÒÖÖÆ¼ÁPralsetinib(BLU-667£¬£¬£¬Gavreto)ÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁÆRETÈÚºÏÑôÐÔ×ªÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)³ÉÈË»¼Õß[1]¡£¡£¡£ ¡£2021Äê3ÔÂ24ÈÕ£¬£¬£¬BLU667(ÆÕÀ­ÌæÄá, ÉÌÆ·Ãû£ºÆÕ¼ª»ª®)»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö(NMPA)Åú×¼£¬£¬£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýº¬²¬»¯ÁƵÄRET»ùÒòÈÚºÏÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬£¬£¬³ÉΪº£ÄÚÊ׸öÒ²ÊÇÏÖÔÚΨһ»ñÅúµÄRETÒÖÖÆ¼Á[1]¡£¡£¡£ ¡£

²»¹ý£¬£¬£¬ÓÌÈçÆäËû°ÐÏòÒ©Ò»Ñù£¬£¬£¬ÄÍÒ©ÊDz»¿É×èÖ¹µÄ¡£¡£¡£ ¡£2020Äê1ÔÂ24ÈÕ£¬£¬£¬¡¶J Thorac Oncol¡·±¨µÀÁË2ÀýRETÈںϷÇСϸ°û·Î°©»¼ÕßÔÚʹÓÃLOXO-292ºó·ºÆðÈܼÁÇ°ÑØÍ»±ä(RET G810R/S/C)£¬£¬£¬½ø¶øµ¼ÖÂLOXO-292ÄÍÒ©¡£¡£¡£ ¡£½á¹¹Ä£×ÓÕ¹Íû£¬£¬£¬RETÈܼÁÇ°ÑØÍ»±äG810R/S/C/VÍ»±äÔÚ¿Õ¼äÉÏ×è°­ÁËSelpercatinibµÄÁ¬Ïµ£¬£¬£¬ÌåÍâÊÔÑé֤ʵ¿¹RET¶à¼¤Ã¸ÒÖÖÆ¼ÁMKIºÍÑ¡ÔñÐÔRET TKIs¾ùʧȥ»îÐÔ£¬£¬£¬Pralsetinib(BLU-667)¶ÔG810SÃô¸Ð[6]¡£¡£¡£ ¡£2021Äê4ÔÂ10ºÅ£¬£¬£¬Loxo Oncology¹«Ë¾±¨µÀ£¬£¬£¬ÔÚ»¼ÕßÖзºÆðRETÈܼÁÇ°ÑØÍ»±äG810λµãºÍÃÅ¿ØÍ»±äV804λµãµÄ˫ͻ±ä£¬£¬£¬¼°M918TλµãºÍÈܼÁÇ°ÑØÍ»±äG810λµãµÄ˫ͻ±ä¡£¡£¡£ ¡£ÌåÍâʵÑéЧ¹ûÏÔʾ£¬£¬£¬RET±¬·¢Ë«Í»±äºó£¬£¬£¬¶ÔSelpercatinib(LOXO-292)ºÍPralsetinib(BLU-667)ÒÖÖÆ¼Á²»Ãô¸Ð[7]¡£¡£¡£ ¡£

 

A

ͼ4. Ñ¡ÔñÐÔRETÒÖÖÆ¼ÁÄÍÒ©ÐÔµÄÄ£Äâ¡£¡£¡£ ¡£

(ͼƬȪԴÓڲο¼×ÊÁÏ[6])

Õë¶ÔRET¼¤Ã¸ÒÖÖÆ¼ÁÒ©Î↑·¢ºÍÐèÇ󣬣¬£¬Ò¼ºÅÓéÀÖ¹¹½¨Ò»ÏµÁÐBa/F3-RET˫ͻ±äµÄ¹¤³Ìϸ°ûÖ꣬£¬£¬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸÐò¼°¶¯ÎïҩЧÆÀ¼Û£¬£¬£¬½Ó´ý¿í´ó¿Í»§×ÉѯÏàÖú¡£¡£¡£ ¡£

ϸ°ûÖêÁбí

A

 

²¿·Öϸ°ûÖêÌåÍâÑéÖ¤Êý¾Ý

A

 

²¿·Öϸ°ûÖêÌåÄÚÄ£×ÓÑéÖ¤Êý¾Ý

BLU-667 in Ba/F3-KIF5B-RET Model

 

BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804M Model

 

BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804L Model

 

BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810C Model

 

BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810R Model

 

BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810S Model

 

²¿·ÖCDXÄ£×ÓÑéÖ¤Êý¾Ý

LOXO-292 in LC-2/ad Model

 

LOXO-292 in TT Model

 

²Î¿¼ÎÄÏ×¼°Í¼Æ¬ÈªÔ´£º

1. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature, 2021 May,17:296–306.

2. To Bud or not to Bud: The RET perspective in CAKUT. Pediatr Nephrol. 2014 Apr; 29(4): 597–608.

3. RET Aberrations in Diverse Cancers. Clin Cancer Res; 23(8) April 15, 2017,1988-1997.

4. Curigliano G, et al. 2021 ASCO, Poster 9089.

5.Öйú·ÇСϸ°û·Î°© RET »ùÒòÈÚºÏÁÙ´²¼ì²âר¼Ò¹²Ê¶. Öлª²¡ÀíѧÔÓÖ¾, 2021, 50(6): 583-591.

6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology Vol. 2020.15 No. 4: 541-549.

7. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Loxo Oncology at Lilly. Presented at: AACR Annual Meeting 2021.

ÕÐÏÍÄÉÊ¿

Ò¼ºÅÓéÀÖ¹«ÖÚºÅ

Ò¼ºÅÓéÀÖ¹«ÖÚºÅ

Á¢ÒìÒ©ÎïÆÀ¼Û

Á¢ÒìÒ©ÎïÆÀ¼Û

ÖÐÒ½¿Æ

ÖпÆÒ½ÂöС³ÌÐò

µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©   
         0551—67129201£¨¹«Ë¾×ܲ¿£©
ÍøÖ·£ºwww.precedo.cn                           
µØµã£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°

Copyright ©  2021 Ò¼ºÅÓéÀÖ °æÈ¨ËùÓР  |   SEO±êÇ©

ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê

%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86

Sorry£¬£¬£¬Ä¿½ñÀ¸Ä¿ÔÝÎÞÄÚÈÝ!

Äú¿ÉÒÔÉó²éÆäËûÀ¸Ä¿»ò·µ»Ø Ê×Ò³

Sorry£¬£¬£¬The current column has no content!

You can view other columns or return Home

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿